Opposing evidence from subsequent studies suggest that G-CSF could be safe after CAR T. Galli et al. reported that patients who received G-CSF starting at five days post-CAR T were not at increased risk of experiencing severe CRS or ICANS [54]. This evidence concerns the gene CSF3 and congenital rubella syndrome.